Annual Drug Patent Expirations for VYVANSE
Vyvanse is a drug marketed by Takeda Pharms Usa and is included in two NDAs. It is available from one supplier. There are eighteen patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for VYVANSE.
This drug has one hundred and forty-four patent family members in twenty-seven countries.
The generic ingredient in VYVANSE is lisdexamfetamine dimesylate. One supplier is listed for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
